New hope for rare immune disorder: ruxolitinib trial targets castleman disease

This study tests the drug ruxolitinib in 14 adults with idiopathic multicentric Castleman disease (iMCD) whose condition did not improve with standard therapies like siltuximab or tocilizumab. The goal is to see if ruxolitinib can improve symptoms such as fatigue, fever, and night sweats, as well as lab markers and lymph node size. Participants will take the drug and be monitored for up to 12 months.